Correlates of Using Medically-Authorized Cannabis in a Large Cohort of People Living with HIV Who Use Cannabis

Overview

Journal AIDS Behav

Specialty Infectious Diseases

Date 2024 Dec 10

PMID 39656341

Authors

Sophie G Coelho

Jeffrey D Wardell

Abigail Kroch

Sergio Rueda

Affiliations

Soon will be listed here.

Abstract

Many people living with HIV (PLWH) use cannabis to manage symptoms, but a large proportion do so without medical cannabis authorization and use cannabis obtained outside the medical stream. In jurisdictions where non-medical cannabis use is legal, PLWH who hold medical cannabis authorization may represent a unique subgroup; yet, research on the correlates of using medical cannabis (authorized by a healthcare provider) in the context of non-medical cannabis legalization is lacking. Thus, this study examined the cannabis- and health-related correlates of medical cannabis use among PLWH in Ontario, Canada, where non-medical cannabis is legal. PLWH (N = 868; 85.37% men, mean age 51.34 years [SD = 12.25]) who were enrolled in the Ontario HIV Treatment Network Cohort Study in 2022 and who reported past-year cannabis use completed an assessment of sociodemographic characteristics, HIV-related variables, cannabis and other substance use, and health-related quality of life. Relatively few participants (n = 122; 14.06%) reported any medical cannabis use, with most (n = 746; 85.94%) reporting exclusive use of non-medical cannabis. Logistic regression analyses showed that greater HIV symptom distress, poorer physical-health-related quality of life, more frequent cannabis use, and using smokeless forms of cannabis were each uniquely associated with increased likelihood of using medical cannabis relative to exclusively using non-medical cannabis. Results suggest that even in jurisdictions where non-medical cannabis is legal, a subset of PLWH continue to access cannabis through the medical stream, and these individuals report distinct patterns of cannabis use and poorer physical health. Findings may inform cannabis policy and clinical care for PLWH who use cannabis.

References

Harris G, Dupuis L, Mugford G, Johnston L, Haase D, Page G . Patterns and correlates of cannabis use among individuals with HIV/AIDS in Maritime Canada. Can J Infect Dis Med Microbiol. 2014; 25(1):e1-7. PMC: 3950986. DOI: 10.1155/2014/301713. View

Pacek L, Towe S, Hobkirk A, Nash D, Goodwin R . Frequency of Cannabis Use and Medical Cannabis Use Among Persons Living With HIV in the United States: Findings From a Nationally Representative Sample. AIDS Educ Prev. 2018; 30(2):169-181. PMC: 6624834. DOI: 10.1521/aeap.2018.30.2.169. View

Shiau S, Arpadi S, Yin M, Martins S . Patterns of drug use and HIV infection among adults in a nationally representative sample. Addict Behav. 2017; 68:39-44. PMC: 5303613. DOI: 10.1016/j.addbeh.2017.01.015. View

Costiniuk C, Saneei Z, Salahuddin S, Cox J, Routy J, Rueda S . Cannabis Consumption in People Living with HIV: Reasons for Use, Secondary Effects, and Opportunities for Health Education. Cannabis Cannabinoid Res. 2019; 4(3):204-213. PMC: 6757238. DOI: 10.1089/can.2018.0068. View

Furler M, Einarson T, Millson M, Walmsley S, Bendayan R . Medicinal and recreational marijuana use by patients infected with HIV. AIDS Patient Care STDS. 2004; 18(4):215-28. DOI: 10.1089/108729104323038892. View

Adams J, Bryant K, Edelman E, Fiellin D, Gaither J, Gordon A . Association of Cannabis, Stimulant, and Alcohol use with Mortality Prognosis Among HIV-Infected Men. AIDS Behav. 2017; 22(4):1341-1351. PMC: 5881942. DOI: 10.1007/s10461-017-1905-4. View

Lake S, Kerr T, Capler R, Shoveller J, Montaner J, Milloy M . High-intensity cannabis use and HIV clinical outcomes among HIV-positive people who use illicit drugs in Vancouver, Canada. Int J Drug Policy. 2017; 42:63-70. PMC: 5423459. DOI: 10.1016/j.drugpo.2017.02.009. View

Montgomery L, Bagot K, Brown J, Haeny A . The Association Between Marijuana Use and HIV Continuum of Care Outcomes: a Systematic Review. Curr HIV/AIDS Rep. 2019; 16(1):17-28. PMC: 6432787. DOI: 10.1007/s11904-019-00422-z. View

Bonn-Miller M, Oser M, Bucossi M, Trafton J . Cannabis use and HIV antiretroviral therapy adherence and HIV-related symptoms. J Behav Med. 2012; 37(1):1-10. DOI: 10.1007/s10865-012-9458-5. View

10.

de Jong B, Prentiss D, McFarland W, Machekano R, Israelski D . Marijuana use and its association with adherence to antiretroviral therapy among HIV-infected persons with moderate to severe nausea. J Acquir Immune Defic Syndr. 2004; 38(1):43-6. DOI: 10.1097/00126334-200501010-00008. View

11.

Mannes Z, Burrell 2nd L, Ferguson E, Zhou Z, Lu H, Somboonwit C . The association of therapeutic versus recreational marijuana use and antiretroviral adherence among adults living with HIV in Florida. Patient Prefer Adherence. 2018; 12:1363-1372. PMC: 6067624. DOI: 10.2147/PPA.S167826. View

12.

Slawson G, Milloy M, Balneaves L, Simo A, Guillemi S, Hogg R . High-intensity cannabis use and adherence to antiretroviral therapy among people who use illicit drugs in a Canadian setting. AIDS Behav. 2014; 19(1):120-7. PMC: 4289662. DOI: 10.1007/s10461-014-0847-3. View

13.

Korthuis P, Zephyrin L, Fleishman J, Saha S, Josephs J, McGrath M . Health-related quality of life in HIV-infected patients: the role of substance use. AIDS Patient Care STDS. 2008; 22(11):859-67. PMC: 2596984. DOI: 10.1089/apc.2008.0005. View

14.

Prentiss D, Power R, Balmas G, Tzuang G, Israelski D . Patterns of marijuana use among patients with HIV/AIDS followed in a public health care setting. J Acquir Immune Defic Syndr. 2004; 35(1):38-45. DOI: 10.1097/00126334-200401010-00005. View

15.

Wardell J, Shuper P, Hendershot C . A longitudinal investigation of the association between cannabis use and alcohol use among people living with HIV. Drug Alcohol Depend. 2018; 193:7-13. DOI: 10.1016/j.drugalcdep.2018.08.026. View

16.

Fischer B, Russell C, Sabioni P, van den Brink W, Le Foll B, Hall W . Lower-Risk Cannabis Use Guidelines: A Comprehensive Update of Evidence and Recommendations. Am J Public Health. 2017; 107(8):e1-e12. PMC: 5508136. DOI: 10.2105/AJPH.2017.303818. View

17.

Fischer B, Robinson T, Bullen C, Curran V, Jutras-Aswad D, Medina-Mora M . Lower-Risk Cannabis Use Guidelines (LRCUG) for reducing health harms from non-medical cannabis use: A comprehensive evidence and recommendations update. Int J Drug Policy. 2021; 99:103381. DOI: 10.1016/j.drugpo.2021.103381. View

18.

Costiniuk C, MacCallum C, Boivin M, Rueda S, Lacasse G, Walsh Z . Why a distinct medical stream is necessary to support patients using cannabis for medical purposes. J Cannabis Res. 2023; 5(1):25. PMC: 10318655. DOI: 10.1186/s42238-023-00195-8. View

19.

Belle-Isle L, Walsh Z, Callaway R, Lucas P, Capler R, Kay R . Barriers to access for Canadians who use cannabis for therapeutic purposes. Int J Drug Policy. 2014; 25(4):691-9. DOI: 10.1016/j.drugpo.2014.02.009. View

20.

Belle-Isle L, Hathaway A . Barriers to access to medical cannabis for Canadians living with HIV/AIDS. AIDS Care. 2007; 19(4):500-6. DOI: 10.1080/09540120701207833. View